FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
Extrapolation from adult data does not work in this case and there is insufficient supporting pediatric data, the Gastrointestinal Drugs Advisory Committee concluded July 21.
You may also be interested in...
Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.
The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.
Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.